Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

Protease Activated Receptor (PAR)

" in MCE Product Catalog:

By Targets:	Protease Activated Receptor (PAR) (35) Apoptosis (3)
By Research Areas:	Cancer (7) Cardiovascular Disease (12) Inflammation/Immunology (16) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Targets Recommended: Protease Activated Receptor (PAR) Virus Protease HCV Protease HIV Protease Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas

HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 *(PAR-1)* agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-P2518A

Protease-Activated Receptor-1, PAR-1 Agonist TFA	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-1, PAR-1 Agonist TFA is a selective proteinase-activated receptor1 *(PAR-1)* agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist TFA corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-P2519

Protease-Activated Receptor-3 (PAR-3) (1-6), human	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-3 (PAR-3) (1-6), human is a proteinase-activated receptor (PAR-3) agonist peptide.

HY-P2519A

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide.

HY-P1308

SLIGRL-NH2 Protease-Activated Receptor-2 Activating Peptide	Protease Activated Receptor (PAR)	Inflammation/Immunology
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (PAR-2).

HY-P1308A

SLIGRL-NH2 TFA Protease-Activated Receptor-2 Activating Peptide TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
SLIGRL-NH2 TFA (Protease-Activated Receptor-2 Activating Peptide TFA) is an agonist of Protease-Activated Receptor-2 (PAR-2).

HY-143313

Protease-Activated Receptor-1 antagonist 1	Protease Activated Receptor (PAR)	Cardiovascular Disease
Protease-Activated Receptor-1 antagonist 1 (Compound 13) is a protease-activated receptor-1 (PAR-1) antagonist with the IC₅₀ of 3 nM by FLIPR technology. Protease-Activated Receptor-1 antagonist 1 can be used for the research of thrombotic cardiovascular, myocardial infarction, and peripheral arterial disease.

HY-P0283

Protease-Activated Receptor-2, amide	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-2, amide (SLIGKV-NH₂) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.

HY-P0297

Protease-Activated Receptor-4
Protease Activated Receptor (PAR) Others

Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4).

Protease-Activated Receptor-4	Protease Activated Receptor (PAR)	Others
Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4).

HY-143314

Protease-Activated Receptor-1 antagonist 2	Protease Activated Receptor (PAR)	Cardiovascular Disease
Protease-Activated Receptor-1 antagonist 2 is an orally active **protease-activated receptor-1** (PAR-1) antagonist, with an IC₅₀ value of 7 nM. Protease-Activated Receptor-1 antagonist 2 has favorable pharmacokinetic properties which is useful in the research of cardiovascular disease (CVD), such as atherosclerosis and restenosis.

HY-138558

PAR-2-IN-1	Protease Activated Receptor (PAR)	Cancer Inflammation/Immunology
PAR-2-IN-1 is a protease-activated receptor-2 (PAR2) signaling pathway inhibitor with anti-inflammatory and anticancer effects.

HY-P0078

TRAP-6 PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective **protease activating receptor 1 (PAR1)** agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4.

HY-14351

AC-264613
Protease Activated Receptor (PAR) Inflammation/Immunology

AC-264613 is a potent and selective protease-activated receptor (PAR-2) agonist with a pEC₅₀ of 7.5.
HY-112558

AZ3451
Protease Activated Receptor (PAR) Inflammation/Immunology

AZ3451 is a potent protease-activated receptor-2 (PAR2) antagonist with IC₅₀ of 23 nM.

AC-264613	Protease Activated Receptor (PAR)	Inflammation/Immunology
AC-264613 is a potent and selective protease-activated receptor (PAR-2) agonist with a pEC₅₀ of 7.5.

AZ3451	Protease Activated Receptor (PAR)	Inflammation/Immunology
AZ3451 is a potent **protease-activated receptor-2 (PAR2)** antagonist with IC₅₀ of 23 nM.

HY-P1313A

PAR 4 (1-6) (TFA) GYPGQV TFA	Protease Activated Receptor (PAR)	Others
PAR 4 (1-6) TFA (GYPGQV TFA), a hexapeptide, is a fragment of protease-activated receptor 4 (PAR₄). PAR 4 (1-6) TFA acts as a PAR₄-specific agonist.

HY-P1260

FSLLRY-NH2
Protease Activated Receptor (PAR) Neurological Disease

FSLLRY-NH2 is a protease-activated receptor 2 (PAR2) inhibitor.
HY-P1260A

FSLLRY-NH2 TFA
Protease Activated Receptor (PAR) Neurological Disease

FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor.
HY-117793

I-191
Protease Activated Receptor (PAR) Cancer

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist.

FSLLRY-NH2	Protease Activated Receptor (PAR)	Neurological Disease
FSLLRY-NH2 is a **protease-activated receptor 2 (PAR2)** inhibitor.

FSLLRY-NH2 TFA	Protease Activated Receptor (PAR)	Neurological Disease
FSLLRY-NH2 TFA is a **protease-activated receptor 2 (PAR2)** inhibitor.

I-191	Protease Activated Receptor (PAR)	Cancer
I-191 is a potent, selective **protease-activated receptor 2 (PAR2)** antagonist.

HY-150790

BMS-986141	Protease Activated Receptor (PAR)	Cardiovascular Disease
BMS-98614 is an orally active, selective thrombin receptor **protease-activated receptor-4 (PAR-4) antagonist with an IC₅₀** value of 0.4 nM. BMS-98614 has excellent antithrombotic effect.

HY-10119

Vorapaxar SCH 530348	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor **protease-activated receptor (PAR-1) antagonist (K_i*=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating* peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.

HY-10119A

Vorapaxar sulfate SCH 530348 sulfate	Protease Activated Receptor (PAR)	Cardiovascular Disease
Vorapaxar sulfate (SCH 530348 sulfate), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor **protease-activated receptor (PAR-1) antagonist (K_i*=8.1 nM). Vorapaxar sulfate inhibits thrombin receptor-activating* peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor **protease-activated receptor-1 (PAR-1)** antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease.

HY-120528A

GB-110 hydrochloride	Protease Activated Receptor (PAR)	Cancer Inflammation/Immunology
GB-110 hydrochloride is a potent, orally active, and nonpeptidic **protease activated receptor 2 (PAR2)** agonist. GB-110 hydrochloride selectively induces PAR2-mediated intracellular Ca²⁺ release in HT29 cells with an EC₅₀ of 0.28 μM.

HY-120528

GB-110	Protease Activated Receptor (PAR)	Cancer Inflammation/Immunology
GB-110 is a potent, orally active, and nonpeptidic **protease activated receptor 2 (PAR2)** agonist. GB-110 selectively induces PAR2-mediated intracellular Ca²⁺ release in HT29 cells with an EC₅₀ of 0.28 μM.

HY-18200B

Atopaxar hydrobromide E5555 hydrobromide; ER 172594-06	Protease Activated Receptor (PAR)	Cardiovascular Disease
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor **protease-activated receptor-1 (PAR-1)** antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease.

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cancer Cardiovascular Disease
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible **protease-activated receptor-1 (PAR1)** antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects.

HY-14994

SCH79797 dihydrochloride	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide **protease activated receptor 1 (PAR1)** antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to *PAR1* with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents *PAR1* activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-14993

SCH79797	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide **protease activated receptor 1 (PAR1)** antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to *PAR1* with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents *PAR1* activation in vascular smooth muscle cells, endothelial cells, and astrocytes.

HY-14350

AC-55541	Protease Activated Receptor (PAR)	Others
AC-55541 is a highly selective **protease-activated receptor 2 (PAR2) agonist (pEC₅₀*=6.7), displays no activity at other PAR* subtypes or at over 30 other receptors involved in nociception and inflammation. AC-55541 has pEC₅₀ values of 5.9 and 6.6 in PI hydrolysis assays and Ca²⁺ mobilization assays and exhibits pronociceptive activity in vivo.

HY-P1310

VKGILS-NH2	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells.

HY-P1310A

VKGILS-NH2 TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells.

HY-19837

BMS-986120	Protease Activated Receptor (PAR)	Inflammation/Immunology
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC₅₀s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects.

HY-13965

Parmodulin 2 ML161	Protease Activated Receptor (PAR)	Cardiovascular Disease
Parmodulin 2 (ML161) is an allosteric inhibitor of **protease-activated receptor 1 (PAR1) with an IC₅₀** of 0.26 μM. Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo.

HY-124748A

ENMD-1068 hydrochloride	Protease Activated Receptor (PAR) Apoptosis	Inflammation/Immunology
ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis.

HY-128345

UDM-001651	Protease Activated Receptor (PAR)	Cardiovascular Disease
UDM-001651 is a potent, selective, and orally bioavailable **protease-activated receptor 4 (PAR4) antagonist (IC₅₀=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC₅₀**=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP).

Cat. No.	Product Name	Target	Research Area

HY-P2518

Protease-Activated Receptor-1, PAR-1 Agonist	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 *(PAR-1)* agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-P2518A

Protease-Activated Receptor-1, PAR-1 Agonist TFA	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-1, PAR-1 Agonist TFA is a selective proteinase-activated receptor1 *(PAR-1)* agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist TFA corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptor.

HY-P2519

Protease-Activated Receptor-3 (PAR-3) (1-6), human	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-3 (PAR-3) (1-6), human is a proteinase-activated receptor (PAR-3) agonist peptide.

HY-P2519A

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide.

HY-P1308

SLIGRL-NH2 Protease-Activated Receptor-2 Activating Peptide	Protease Activated Receptor (PAR)	Inflammation/Immunology
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (PAR-2).

HY-P1308A

SLIGRL-NH2 TFA Protease-Activated Receptor-2 Activating Peptide TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
SLIGRL-NH2 TFA (Protease-Activated Receptor-2 Activating Peptide TFA) is an agonist of Protease-Activated Receptor-2 (PAR-2).

HY-P1312

LRGILS-NH2
Peptides Others

LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

LRGILS-NH2	Peptides	Others
LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

HY-P0283

Protease-Activated Receptor-2, amide	Protease Activated Receptor (PAR)	Cancer
Protease-Activated Receptor-2, amide (SLIGKV-NH₂) is a highly potent protease-activated receptor-2 (PAR2) activating peptide.

HY-P0297

Protease-Activated Receptor-4
Protease Activated Receptor (PAR) Others

Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4).
HY-P1312A

LRGILS-NH2 TFA
Peptides Others

LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

Protease-Activated Receptor-4	Protease Activated Receptor (PAR)	Others
Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4).

LRGILS-NH2 TFA	Peptides	Others
LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide.

HY-P0078

TRAP-6 PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6	Protease Activated Receptor (PAR)	Inflammation/Immunology
TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective **protease activating receptor 1 (PAR1)** agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4.

HY-P4004

PAR-4 (1-6) amide (human)	Peptides	Inflammation/Immunology
PAR-4 (1-6) amide human is an N-terminal fragment of protease-activated receptor 4 (PAR4). PAR-4 (1-6) amide human induce platelet aggregation.

HY-P1313A

PAR 4 (1-6) (TFA) GYPGQV TFA	Protease Activated Receptor (PAR)	Others
PAR 4 (1-6) TFA (GYPGQV TFA), a hexapeptide, is a fragment of protease-activated receptor 4 (PAR₄). PAR 4 (1-6) TFA acts as a PAR₄-specific agonist.

HY-P1260

FSLLRY-NH2
Protease Activated Receptor (PAR) Neurological Disease

FSLLRY-NH2 is a protease-activated receptor 2 (PAR2) inhibitor.
HY-P1260A

FSLLRY-NH2 TFA
Protease Activated Receptor (PAR) Neurological Disease

FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor.

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cancer Cardiovascular Disease
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible **protease-activated receptor-1 (PAR1)** antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects.

HY-P1310

VKGILS-NH2	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 has no effect on DNA synthesis in cells.

HY-P1310A

VKGILS-NH2 TFA	Protease Activated Receptor (PAR)	Inflammation/Immunology
VKGILS-NH2 TFA is a reversed amino acid sequence control peptide for SLIGKV-NH2 (protease-activated receptor 2 (PAR2) agonist). VKGILS-NH2 TFA has no effect on DNA synthesis in cells.

Cat. No.	Product Name	Species	Source

HY-P73612

Thrombin Receptor/PAR1 Protein, Human (HEK293, His)
Cf2r; CF2RHTR; F2R; HTR; PAR1; Protease-Activated Receptor 1
Human HEK293